Cesar Perez/LinkedIn
May 29, 2025, 03:51
Cesar Perez: Exciting update in lung cancer treatment being presented at ASCO2025
Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared on LinkedIn:
“KRAS G12C moves into the frontline! Exciting update in lung cancer treatment being presented at ASCO2025.
Join us at the Lung Cancer Rapid Oral Session for the presentation by my co-investigator Dr. Dragnev: Safety and efficacy of olomorasib (KRAS G12C inhibitor) + pembrolizumab in first-line NSCLC.
ORR: 70% | DCR: 90%
Consistent across all PD-L1 levels – including PD-L1 <1
Only 5% (2 patients) discontinued combination therapy due to toxicity. Strong signal of activity for what used to be the un-druggable target.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11